Represents the amortization of capitalized fees paid to a related party.

No definition available.

Name:	inva_AmortizationOfCapitalizedFeesPaidToRelatedParty
Namespace Prefix:	inva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the royalty rate for combination products.

+ References

No definition available.

+ Details

Name:	inva_CollaborativeArrangementAnnualRoyaltiesAsPercentageOfNetSalesForCombinationProducts
Namespace Prefix:	inva_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the maximum amount of potential milestone payments that could be payable.

+ References

No definition available.

+ Details

Name:	inva_CollaborativeArrangementObligationForMilestonePayments
Namespace Prefix:	inva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Represents the amount of registrational and launch-related milestone fee paid under the collaborative arrangement.

+ References

No definition available.

+ Details

Name:	inva_CollaborativeArrangementRegistrationalAndLaunchRelatedMilestoneFeesPaid
Namespace Prefix:	inva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents the royalty rate which the entity will receive under the collaboration agreement on the first defined level of annual global net sales.

+ References

No definition available.

+ Details

Name:	inva_CollaborativeArrangementRoyaltyRateDefinedLevelOne
Namespace Prefix:	inva_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the royalty rate which the entity will receive under the collaboration agreement on sales which exceed the first defined level of annual global net sales.

+ References

No definition available.

+ Details

Name:	inva_CollaborativeArrangementRoyaltyRateDefinedLevelTwo
Namespace Prefix:	inva_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the annual global net sales amount which determines the royalty rate applied under the collaboration arrangement.

+ References

No definition available.

+ Details

Name:	inva_CollaborativeArrangementSpecifiedSalesLevelForDeterminingRoyaltyRate
Namespace Prefix:	inva_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents the percentage of economic interest in any future payments made under the agreements.

+ References

No definition available.

+ Details

Name:	inva_PercentageOfEconomicInterestOnFuturePaymentsUnderAgreements
Namespace Prefix:	inva_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise and net of capitalized fees paid to a related party.

+ References

No definition available.

+ Details

Name:	inva_RevenueFromContractWithCustomerExcludingAssessedTaxNetOfAmortizationOfCapitalizedFeesPaidToRelatedParty
Namespace Prefix:	inva_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_DisaggregationOfRevenueLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 32
-Paragraph 2A
-URI http://asc.fasb.org/extlink&oid=82859839&loc=SL82860478-203043

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82913847&loc=SL49130543-203045

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=82913847&loc=SL49130539-203045

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=82913847&loc=SL49130545-203045

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 225
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.1(e))
-URI http://asc.fasb.org/extlink&oid=63488584&loc=d3e20235-122688

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 225
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07.1(c))
-URI http://asc.fasb.org/extlink&oid=6488393&loc=d3e606610-122999

+ Details

Name:	us-gaap_RevenueFromRelatedParties
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).

+ References

+ Details

Name:	us-gaap_Revenues
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_ProductOrServiceAxis=inva_RoyaltyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=inva_LicenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=inva_GSKMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=inva_LABACollaborationAndStrategicAllianceAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=inva_LABACollaborationMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=inva_LongActingBeta2AgonistRelvarBreoMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=inva_LongActingBeta2AgonistAnoroMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ProductOrServiceAxis=inva_TrelegyElliptaMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=inva_StrategicAllianceAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Revenue Recognition and Collaborative Arrangements (Details) - USD ($) $ in Thousands	3 Months Ended		12 Months Ended
	Mar. 31, 2018	Mar. 31, 2017	Dec. 31, 2014
Revenue Recognition and Collaborative Arrangements
Total net revenue	$ 52,380	$ 40,492
Royalty Revenue
Revenue Recognition and Collaborative Arrangements
Less: amortization of capitalized fees paid to a related party	(3,456)	(3,456)
Royalty revenue	52,380	40,271
License
Revenue Recognition and Collaborative Arrangements
Strategic alliance - MABA program license	0	221
GSK
Revenue Recognition and Collaborative Arrangements
Total net revenue	$ 52,380	40,492
LABA collaboration and Strategic Alliance agreements \| GSK
Revenue Recognition and Collaborative Arrangements
Percentage of economic interest in any future payments made under the agreements	15.00%
Long-acting beta agonist (LABA) collaboration \| GSK
Revenue Recognition and Collaborative Arrangements
Milestone fees paid			$ 220,000
Obligation for milestone payments	$ 0
Long-acting beta agonist (LABA) collaboration \| GSK \| Royalty Revenue
Revenue Recognition and Collaborative Arrangements
Royalties from a related party	55,836	43,727
Less: amortization of capitalized fees paid to a related party	(3,456)	(3,456)
Royalty revenue	52,380	40,271
Long-acting beta agonist (LABA) collaboration \| GSK \| RELVAR/BREO
Revenue Recognition and Collaborative Arrangements
Royalties from a related party	$ 46,160	38,689
Royalty rate for first level of annual global net sales (as a percent)	15.00%
Annual global sales level used to determine royalty rate	$ 3,000,000
Royalty rate for sales above first level of annual global net sales (as a percent)	5.00%
Long-acting beta agonist (LABA) collaboration \| GSK \| ANORO
Revenue Recognition and Collaborative Arrangements
Royalties from a related party	$ 8,724	5,038
Long-acting beta agonist (LABA) collaboration \| GSK \| ANORO \| Minimum
Revenue Recognition and Collaborative Arrangements
Royalty rate for combination products (as a percent)	6.50%
Long-acting beta agonist (LABA) collaboration \| GSK \| ANORO \| Maximum
Revenue Recognition and Collaborative Arrangements
Royalty rate for combination products (as a percent)	10.00%
Long-acting beta agonist (LABA) collaboration \| GSK \| TRELEGY
Revenue Recognition and Collaborative Arrangements
Royalties from a related party	$ 952	0
Long-acting beta agonist (LABA) collaboration \| GSK \| TRELEGY \| Minimum
Revenue Recognition and Collaborative Arrangements
Royalty rate for combination products (as a percent)	6.50%
Long-acting beta agonist (LABA) collaboration \| GSK \| TRELEGY \| Maximum
Revenue Recognition and Collaborative Arrangements
Royalty rate for combination products (as a percent)	10.00%
Strategic alliance - MABA program license \| GSK \| License
Revenue Recognition and Collaborative Arrangements
Strategic alliance - MABA program license	$ 0	$ 221